Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent PaymentsAntev is developing Teverelix, A…
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025CORAL GABLES, Fla., April 27, 2025…
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3%…
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf…
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder…
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of…
TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates…
GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed…
CrazyBulk CrazyBulk NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Benefits of Legal Steroids for Building Muscle Legal steroids are…
MIAMI, April 25, 2025 /PRNewswire/ -- Symphony Robotics, a pioneer in advanced neurosurgical micro-robotics, today announced the appointment of renowned…